Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study
Background: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in...
Gespeichert in:
| Veröffentlicht in: | International psychogeriatrics 2013-08, Vol.25 (8), p.1335-1344 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1344 |
|---|---|
| container_issue | 8 |
| container_start_page | 1335 |
| container_title | International psychogeriatrics |
| container_volume | 25 |
| creator | Hallikainen, Ilona Hänninen, Tuomo Fraunberg, Mikael Hongisto, Kristiina Välimäki, Tarja Hiltunen, Asta Karppi, Pertti Sivenius, Juhani Soininen, Hilkka Koivisto, Anne M. |
| description | Background: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in progression between patients with very mild or mild baseline AD. Methods: In this three-year follow-up of 115 ALSOVA study patients with clinical dementia ratings (CDR) of very mild (0.5) or mild (1) AD, we analyzed total CERAD-NB, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and Clinical Dementia Rating Sum of Boxes scores. Correlations were identified with efficacy parameters. Results: Over three years, total CERAD-NB declined significantly in both groups. Annual change rates of total CERAD-NB were also significant. Total CERAD-NB revealed annual differences in cognition between study groups, while MMSE did not. Total CERAD-NB correlated well with other cognitive and global measures, but not with NPI. For almost two years, the CDR-0.5 group maintained a higher activities of daily living than the CDR-1 group exhibited at baseline. Furthermore, the CDR-0.5 group showed milder neuropsychiatric symptoms at the end of follow-up than the CDR-1 group showed at baseline. Conclusions: The CERAD total score is a suitable and sensitive follow-up tool in longitudinal AD trials. Cognition progression rates did not significantly differ between study groups; however, patients with very mild AD at baseline had milder neuropsychiatric symptoms after long-term follow-up. This emphasizes the importance of early diagnosis and assessment of neuropsychiatric symptoms at the diagnostic visit and during follow-up. |
| doi_str_mv | 10.1017/S1041610213000653 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492622926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S1041610213000653</cupid><els_id>S1041610224014194</els_id><sourcerecordid>1381100883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-c7892683f9962e15e2e6d09c4bea1011356b0efc23806248c10b4159f4d58dd73</originalsourceid><addsrcrecordid>eNqFkd2L1DAUxYso7rr6B_giARF9qd6bpF_rUx3XDxxccVV8K2lyO5OlbcakVca_3gwzfqCoL0ng_O7hnpwkuY3wEAGLRxcIEnMEjgIA8kxcSY6xkJhyEB-vxneU051-lNwI4RKAZwLl9eSIi7zIhYTjZHrj3cpTCNaNzHWs7r-uyQ7k7wdmbCAViJnZ23HFFJvWnijdkvKsc33vvqTzhs1hJ05rYouzt_XT9PUTNrlJ9Sxo5-mUvZrdxjpWLy_OP9QsTLPZ3kyudaoPdOtwnyTvn529W7xIl-fPXy7qZaplKadUF2XF81J0VZVzwow45QYqLVtSMT-KLG-BOs1FCTmXpUZoJWZVJ01WGlOIk-TB3nfj3aeZwtQMNmjqezWSm0ODMvpzHo__o6JEBChLEdG7v6GXbvZjDBINscSMxwoihXtKexeCp67ZeDsov20Qml17zR_txZk7B-e5Hcj8mPheVwTuHQAVtOo7r0Ztw0-uyCRUkEXu8Z6j-LufLfkmaEujJmM96akxzv5zDXFYXQ2tt2ZFvyT869Q3TKq_6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1418152741</pqid></control><display><type>article</type><title>Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Cambridge Journals</source><creator>Hallikainen, Ilona ; Hänninen, Tuomo ; Fraunberg, Mikael ; Hongisto, Kristiina ; Välimäki, Tarja ; Hiltunen, Asta ; Karppi, Pertti ; Sivenius, Juhani ; Soininen, Hilkka ; Koivisto, Anne M.</creator><creatorcontrib>Hallikainen, Ilona ; Hänninen, Tuomo ; Fraunberg, Mikael ; Hongisto, Kristiina ; Välimäki, Tarja ; Hiltunen, Asta ; Karppi, Pertti ; Sivenius, Juhani ; Soininen, Hilkka ; Koivisto, Anne M. ; ALSOVA study group</creatorcontrib><description>Background: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in progression between patients with very mild or mild baseline AD. Methods: In this three-year follow-up of 115 ALSOVA study patients with clinical dementia ratings (CDR) of very mild (0.5) or mild (1) AD, we analyzed total CERAD-NB, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and Clinical Dementia Rating Sum of Boxes scores. Correlations were identified with efficacy parameters. Results: Over three years, total CERAD-NB declined significantly in both groups. Annual change rates of total CERAD-NB were also significant. Total CERAD-NB revealed annual differences in cognition between study groups, while MMSE did not. Total CERAD-NB correlated well with other cognitive and global measures, but not with NPI. For almost two years, the CDR-0.5 group maintained a higher activities of daily living than the CDR-1 group exhibited at baseline. Furthermore, the CDR-0.5 group showed milder neuropsychiatric symptoms at the end of follow-up than the CDR-1 group showed at baseline. Conclusions: The CERAD total score is a suitable and sensitive follow-up tool in longitudinal AD trials. Cognition progression rates did not significantly differ between study groups; however, patients with very mild AD at baseline had milder neuropsychiatric symptoms after long-term follow-up. This emphasizes the importance of early diagnosis and assessment of neuropsychiatric symptoms at the diagnostic visit and during follow-up.</description><identifier>ISSN: 1041-6102</identifier><identifier>EISSN: 1741-203X</identifier><identifier>DOI: 10.1017/S1041610213000653</identifier><identifier>PMID: 23676340</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Activities of Daily Living ; Adult and adolescent clinical studies ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer Disease - psychology ; Alzheimer's disease ; Biological and medical sciences ; CERAD ; Cognition ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; dementia ; Dementia - diagnosis ; Dementia - psychology ; Disease Progression ; Female ; Follow-Up Studies ; Geriatrics ; Humans ; Male ; Medical sciences ; Neurology ; neuropsychiatric symptoms ; Neuropsychological Tests ; Organic mental disorders. Neuropsychology ; progression ; Prospective Studies ; Psychiatric Status Rating Scales ; Psychological tests ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Socioeconomic Factors ; Surveys and Questionnaires</subject><ispartof>International psychogeriatrics, 2013-08, Vol.25 (8), p.1335-1344</ispartof><rights>Copyright © International Psychogeriatric Association 2013</rights><rights>2013 Copyright © International Psychogeriatric Association 2013</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-c7892683f9962e15e2e6d09c4bea1011356b0efc23806248c10b4159f4d58dd73</citedby><cites>FETCH-LOGICAL-c484t-c7892683f9962e15e2e6d09c4bea1011356b0efc23806248c10b4159f4d58dd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S1041610213000653/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,776,780,12825,27901,27902,30976,55603</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27540905$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23676340$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hallikainen, Ilona</creatorcontrib><creatorcontrib>Hänninen, Tuomo</creatorcontrib><creatorcontrib>Fraunberg, Mikael</creatorcontrib><creatorcontrib>Hongisto, Kristiina</creatorcontrib><creatorcontrib>Välimäki, Tarja</creatorcontrib><creatorcontrib>Hiltunen, Asta</creatorcontrib><creatorcontrib>Karppi, Pertti</creatorcontrib><creatorcontrib>Sivenius, Juhani</creatorcontrib><creatorcontrib>Soininen, Hilkka</creatorcontrib><creatorcontrib>Koivisto, Anne M.</creatorcontrib><creatorcontrib>ALSOVA study group</creatorcontrib><title>Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study</title><title>International psychogeriatrics</title><addtitle>Int. Psychogeriatr</addtitle><description>Background: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in progression between patients with very mild or mild baseline AD. Methods: In this three-year follow-up of 115 ALSOVA study patients with clinical dementia ratings (CDR) of very mild (0.5) or mild (1) AD, we analyzed total CERAD-NB, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and Clinical Dementia Rating Sum of Boxes scores. Correlations were identified with efficacy parameters. Results: Over three years, total CERAD-NB declined significantly in both groups. Annual change rates of total CERAD-NB were also significant. Total CERAD-NB revealed annual differences in cognition between study groups, while MMSE did not. Total CERAD-NB correlated well with other cognitive and global measures, but not with NPI. For almost two years, the CDR-0.5 group maintained a higher activities of daily living than the CDR-1 group exhibited at baseline. Furthermore, the CDR-0.5 group showed milder neuropsychiatric symptoms at the end of follow-up than the CDR-1 group showed at baseline. Conclusions: The CERAD total score is a suitable and sensitive follow-up tool in longitudinal AD trials. Cognition progression rates did not significantly differ between study groups; however, patients with very mild AD at baseline had milder neuropsychiatric symptoms after long-term follow-up. This emphasizes the importance of early diagnosis and assessment of neuropsychiatric symptoms at the diagnostic visit and during follow-up.</description><subject>Activities of Daily Living</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Biological and medical sciences</subject><subject>CERAD</subject><subject>Cognition</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>dementia</subject><subject>Dementia - diagnosis</subject><subject>Dementia - psychology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>neuropsychiatric symptoms</subject><subject>Neuropsychological Tests</subject><subject>Organic mental disorders. Neuropsychology</subject><subject>progression</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychological tests</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Socioeconomic Factors</subject><subject>Surveys and Questionnaires</subject><issn>1041-6102</issn><issn>1741-203X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkd2L1DAUxYso7rr6B_giARF9qd6bpF_rUx3XDxxccVV8K2lyO5OlbcakVca_3gwzfqCoL0ng_O7hnpwkuY3wEAGLRxcIEnMEjgIA8kxcSY6xkJhyEB-vxneU051-lNwI4RKAZwLl9eSIi7zIhYTjZHrj3cpTCNaNzHWs7r-uyQ7k7wdmbCAViJnZ23HFFJvWnijdkvKsc33vvqTzhs1hJ05rYouzt_XT9PUTNrlJ9Sxo5-mUvZrdxjpWLy_OP9QsTLPZ3kyudaoPdOtwnyTvn529W7xIl-fPXy7qZaplKadUF2XF81J0VZVzwow45QYqLVtSMT-KLG-BOs1FCTmXpUZoJWZVJ01WGlOIk-TB3nfj3aeZwtQMNmjqezWSm0ODMvpzHo__o6JEBChLEdG7v6GXbvZjDBINscSMxwoihXtKexeCp67ZeDsov20Qml17zR_txZk7B-e5Hcj8mPheVwTuHQAVtOo7r0Ztw0-uyCRUkEXu8Z6j-LufLfkmaEujJmM96akxzv5zDXFYXQ2tt2ZFvyT869Q3TKq_6g</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Hallikainen, Ilona</creator><creator>Hänninen, Tuomo</creator><creator>Fraunberg, Mikael</creator><creator>Hongisto, Kristiina</creator><creator>Välimäki, Tarja</creator><creator>Hiltunen, Asta</creator><creator>Karppi, Pertti</creator><creator>Sivenius, Juhani</creator><creator>Soininen, Hilkka</creator><creator>Koivisto, Anne M.</creator><general>Cambridge University Press</general><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88J</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130801</creationdate><title>Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study</title><author>Hallikainen, Ilona ; Hänninen, Tuomo ; Fraunberg, Mikael ; Hongisto, Kristiina ; Välimäki, Tarja ; Hiltunen, Asta ; Karppi, Pertti ; Sivenius, Juhani ; Soininen, Hilkka ; Koivisto, Anne M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-c7892683f9962e15e2e6d09c4bea1011356b0efc23806248c10b4159f4d58dd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Activities of Daily Living</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Biological and medical sciences</topic><topic>CERAD</topic><topic>Cognition</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>dementia</topic><topic>Dementia - diagnosis</topic><topic>Dementia - psychology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>neuropsychiatric symptoms</topic><topic>Neuropsychological Tests</topic><topic>Organic mental disorders. Neuropsychology</topic><topic>progression</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychological tests</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Socioeconomic Factors</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hallikainen, Ilona</creatorcontrib><creatorcontrib>Hänninen, Tuomo</creatorcontrib><creatorcontrib>Fraunberg, Mikael</creatorcontrib><creatorcontrib>Hongisto, Kristiina</creatorcontrib><creatorcontrib>Välimäki, Tarja</creatorcontrib><creatorcontrib>Hiltunen, Asta</creatorcontrib><creatorcontrib>Karppi, Pertti</creatorcontrib><creatorcontrib>Sivenius, Juhani</creatorcontrib><creatorcontrib>Soininen, Hilkka</creatorcontrib><creatorcontrib>Koivisto, Anne M.</creatorcontrib><creatorcontrib>ALSOVA study group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>International psychogeriatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hallikainen, Ilona</au><au>Hänninen, Tuomo</au><au>Fraunberg, Mikael</au><au>Hongisto, Kristiina</au><au>Välimäki, Tarja</au><au>Hiltunen, Asta</au><au>Karppi, Pertti</au><au>Sivenius, Juhani</au><au>Soininen, Hilkka</au><au>Koivisto, Anne M.</au><aucorp>ALSOVA study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study</atitle><jtitle>International psychogeriatrics</jtitle><addtitle>Int. Psychogeriatr</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>25</volume><issue>8</issue><spage>1335</spage><epage>1344</epage><pages>1335-1344</pages><issn>1041-6102</issn><eissn>1741-203X</eissn><abstract>Background: We studied the suitability of The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) total score for monitoring Alzheimer's disease (AD) progression in early-diagnosed medicated patients. We also investigated possible differences in progression between patients with very mild or mild baseline AD. Methods: In this three-year follow-up of 115 ALSOVA study patients with clinical dementia ratings (CDR) of very mild (0.5) or mild (1) AD, we analyzed total CERAD-NB, Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, and Clinical Dementia Rating Sum of Boxes scores. Correlations were identified with efficacy parameters. Results: Over three years, total CERAD-NB declined significantly in both groups. Annual change rates of total CERAD-NB were also significant. Total CERAD-NB revealed annual differences in cognition between study groups, while MMSE did not. Total CERAD-NB correlated well with other cognitive and global measures, but not with NPI. For almost two years, the CDR-0.5 group maintained a higher activities of daily living than the CDR-1 group exhibited at baseline. Furthermore, the CDR-0.5 group showed milder neuropsychiatric symptoms at the end of follow-up than the CDR-1 group showed at baseline. Conclusions: The CERAD total score is a suitable and sensitive follow-up tool in longitudinal AD trials. Cognition progression rates did not significantly differ between study groups; however, patients with very mild AD at baseline had milder neuropsychiatric symptoms after long-term follow-up. This emphasizes the importance of early diagnosis and assessment of neuropsychiatric symptoms at the diagnostic visit and during follow-up.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>23676340</pmid><doi>10.1017/S1041610213000653</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1041-6102 |
| ispartof | International psychogeriatrics, 2013-08, Vol.25 (8), p.1335-1344 |
| issn | 1041-6102 1741-203X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1492622926 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Cambridge Journals |
| subjects | Activities of Daily Living Adult and adolescent clinical studies Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - psychology Alzheimer's disease Biological and medical sciences CERAD Cognition Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases dementia Dementia - diagnosis Dementia - psychology Disease Progression Female Follow-Up Studies Geriatrics Humans Male Medical sciences Neurology neuropsychiatric symptoms Neuropsychological Tests Organic mental disorders. Neuropsychology progression Prospective Studies Psychiatric Status Rating Scales Psychological tests Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Socioeconomic Factors Surveys and Questionnaires |
| title | Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A24%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progression%20of%20Alzheimer's%20disease%20during%20a%20three-year%20follow-up%20using%20the%20CERAD-NB%20total%20score:%20Kuopio%20ALSOVA%20study&rft.jtitle=International%20psychogeriatrics&rft.au=Hallikainen,%20Ilona&rft.aucorp=ALSOVA%20study%20group&rft.date=2013-08-01&rft.volume=25&rft.issue=8&rft.spage=1335&rft.epage=1344&rft.pages=1335-1344&rft.issn=1041-6102&rft.eissn=1741-203X&rft_id=info:doi/10.1017/S1041610213000653&rft_dat=%3Cproquest_cross%3E1381100883%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1418152741&rft_id=info:pmid/23676340&rft_cupid=10_1017_S1041610213000653&rft_els_id=S1041610224014194&rfr_iscdi=true |